Atricure 

$27.98
12
+$0.00+0% Tuesday 20:00

Statistics

Day High
28.85
Day Low
27.59
52W High
43.18
52W Low
25.36
Volume
675,617
Avg. Volume
-
Mkt Cap
1.39B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.33
-0.21
-0.08
0.04
Expected EPS
-0.00625
Actual EPS
N/A

Financials

-2.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.07BRevenue
-22.9MNet Income

Analyst Ratings

52.20Average Price Target
The highest estimate is 55.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATRC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap102.97B
Medtronic offers a wide range of medical devices for cardiac and vascular surgeries, directly competing with AtriCure's atrial fibrillation products.
Boston Scientific
BSX
Mkt Cap69.72B
Boston Scientific competes in the cardiac surgery space, particularly with products for electrophysiology, which overlaps with AtriCure's offerings.
Abbott Laboratories
ABT
Mkt Cap153.59B
Abbott Laboratories provides medical devices, including heart monitors and ablation catheters, that compete with AtriCure's atrial fibrillation solutions.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its medical device division, offers products that compete in the surgical and cardiovascular arenas, similar to AtriCure's market.
Smith & Nephew
SNN
Mkt Cap12.95B
Smith & Nephew, while known for orthopedics, has been expanding into surgical devices that could compete with AtriCure's portfolio.
Edwards Lifesciences
EW
Mkt Cap49.01B
Edwards Lifesciences specializes in heart valves and hemodynamic monitoring, which places it in competition with AtriCure for certain cardiac surgery applications.
Zimmer Biomet
ZBH
Mkt Cap17.13B
Zimmer Biomet, primarily focused on musculoskeletal healthcare, has been venturing into surgical solutions that could overlap with AtriCure's market.
Stryker
SYK
Mkt Cap119.69B
Stryker focuses on a broad range of medical technologies, including surgical equipment that could compete with AtriCure's offerings.
Intuitive Surgical
ISRG
Mkt Cap145.58B
Intuitive Surgical, known for its da Vinci surgical systems, competes in the broader surgical device market, impacting companies like AtriCure that offer surgical solutions.

About

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Show more...
CEO
Mr. Michael H. Carrel
Employees
1300
Country
United States
ISIN
US04963C2098

Listings

0 Comments

Share your thoughts

FAQ

What is Atricure stock price today?
The current price of ATRC is $27.98 USD — it has increased by +0% in the past 24 hours. Watch Atricure stock price performance more closely on the chart.
What is Atricure stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Atricure stocks are traded under the ticker ATRC.
Is Atricure stock price growing?
ATRC stock has risen by +1.71% compared to the previous week, the month change is a -0.5% fall, over the last year Atricure has showed a -14.17% decrease.
What is Atricure market cap?
Today Atricure has the market capitalization of 1.39B
When is the next Atricure earnings date?
Atricure is going to release the next earnings report on August 04, 2026.
What were Atricure earnings last quarter?
ATRC earnings for the last quarter are 0 USD per share, whereas the estimation was -0.06 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Atricure revenue for the last year?
Atricure revenue for the last year amounts to 1.07B USD.
What is Atricure net income for the last year?
ATRC net income for the last year is -22.9M USD.
How many employees does Atricure have?
As of June 17, 2026, the company has 1,300 employees.
In which sector is Atricure located?
Atricure operates in the Health & Wellness sector.
When did Atricure complete a stock split?
Atricure has not had any recent stock splits.
Where is Atricure headquartered?
Atricure is headquartered in Mason, United States.